Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system.
(2014) In Clinical Pharmacology and Therapeutics 96(4). p.477-481- Abstract
- Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 24 June 2014; doi:10.1038/clpt.2014.138.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4526872
- author
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Pharmacology and Therapeutics
- volume
- 96
- issue
- 4
- pages
- 477 - 481
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000342675400026
- pmid:24960520
- scopus:84921668512
- ISSN
- 1532-6535
- DOI
- 10.1038/clpt.2014.138
- language
- English
- LU publication?
- yes
- id
- 786117e8-9d6f-4277-a1f9-893eaaff663d (old id 4526872)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24960520?dopt=Abstract
- date added to LUP
- 2016-04-01 11:04:48
- date last changed
- 2022-01-26 05:10:50
@article{786117e8-9d6f-4277-a1f9-893eaaff663d, abstract = {{Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 24 June 2014; doi:10.1038/clpt.2014.138.}}, author = {{Wadelius, Mia and E Marshall, Sara and Islander, Gunilla and Nordang, Leif and Karawajczyk, Malgorzata and Yue, Qun-Ying and Terreehorst, Ingrid and Baranova, Ekaterina V and Hugosson, Svante and Sköldefors, Karin and Pirmohamed, Munir and van der Zee, Anke-Hilse Maitland and Alfirevic, Ana and Hallberg, Pär and N A Palmer, Colin}}, issn = {{1532-6535}}, language = {{eng}}, number = {{4}}, pages = {{477--481}}, publisher = {{Nature Publishing Group}}, series = {{Clinical Pharmacology and Therapeutics}}, title = {{Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system.}}, url = {{http://dx.doi.org/10.1038/clpt.2014.138}}, doi = {{10.1038/clpt.2014.138}}, volume = {{96}}, year = {{2014}}, }